



# PACIFIC EDGE

CAPITAL RAISING PRESENTATION

23 SEPTEMBER 2021



**PACIFIC EDGE**  
CANCER DIAGNOSTICS COMPANY

# IMPORTANT NOTICE AND DISCLAIMER

## Information of a general nature

This presentation has been prepared by Pacific Edge Limited (PEL). The information in this presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in PEL or that would be required in a product disclosure statement, prospectus, or other disclosure document for the purposes of the New Zealand Financial Markets Conduct Act 2013 (FMCA) or the Australian Corporations Act 2001 (Cth). PEL is subject to a disclosure obligation that requires it to notify certain material information to NZX Limited (NZX) and ASX Limited (ASX) for the purpose of that information being made available to participants in the market and that information can be found by visiting [www.nzx.com/companies/PEB](http://www.nzx.com/companies/PEB) and [www.asx.com.au](http://www.asx.com.au). This presentation should be read in conjunction with PEL's other periodic and continuous disclosure announcements released to NZX.

## Proposed offer

This presentation has been prepared by PEL in relation to the proposed offer of fully paid ordinary shares in PEL (New Shares) pursuant to a private placement to institutional and other selected investors, and subsequent share purchase plan for existing shareholders with a registered address in New Zealand, in each case under clause 19 of Schedule 1 of the FMCA (Offer). PEL reserves the right to vary the dates of the Offer (either generally or in particular cases) or to withdraw the Offer without prior notice. Notwithstanding the proposed Offer, this presentation is for information purposes only and is not itself an invitation or offer of financial products for subscription, purchase or sale in any jurisdiction. Any decision to purchase New Shares in the Offer must be made on the terms set out in a separate offer document (Offer Document). Any shareholder or investor who wishes to apply for New Shares under the Offer will need to apply in accordance with the instructions contained in the Offer Document.

## NZX

The New Shares have been accepted for quotation by NZX and will be quoted on the NZX Main Board following completion of allotment procedures. However NZX accepts no responsibility for any statement in this document. NZX is a licensed market operator, and the NZX Main Board is a licensed market regulated under the FMCA.

## ASX

PEL has been admitted to the official list of ASX as a foreign exempt issuer, immediately prior to the announcement of the Offer. PEL shares will commence trading on ASX following completion of the private placement. PEL will apply for quotation of the New Shares on the market operated by ASX following completion of the allotment procedures. ASX does not accept any responsibility for any statements in this document.

## Not financial product advice

This presentation does not constitute legal, financial, tax, financial product advice or investment advice or a recommendation to acquire PEL securities, and has been prepared without taking into account the objectives, financial situation or needs of investors. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs and consult an NZX Firm, solicitor, accountant or other professional advisor if necessary.

## Forward-looking statements

This presentation contains forward-looking statements that reflect PEL's current views with respect to future events. Forward-looking statements, by their very nature, involve inherent risks and uncertainties. Many of those risks and uncertainties are matters which are beyond PEL's control and could cause actual results to differ from those predicted. Variations could either be materially positive or materially negative. The information is stated only as at the date of this presentation. Except as required by law or regulation (including the NZX Listing Rules and ASX Listing Rules), PEL undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. To the maximum extent permitted by law, the directors of PEL, PEL and any of its related bodies corporate and affiliates, and their respective officers, partners, employees, agents, associates and advisers do not make any representation or warranty, express or implied, as to the accuracy, reliability or completeness of such information, or the likelihood of fulfilment of any forward-looking statement or any event or results expressed or implied in any forward-looking statement, and disclaim all responsibility and liability for these forward-looking statements (including, without limitation, liability for negligence).

## Financial data

All dollar values are in New Zealand dollars unless otherwise stated. This presentation should be read in conjunction with, and subject to, the explanations and views of future outlook on market conditions, earnings and activities given in the announcements relating to the results, and annual report, for the year ended 31 March 2021.

## Effect of rounding

A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation.

## Past performance

Investors should note that past performance, including past share price performance, cannot be relied upon as an indicator of (and provides no guidance as to) future PEL performance, including future financial position or share price performance.

## Investment risk

An investment in securities of PEL is subject to investment risk and other known and unknown risks, some of which are beyond the control of PEL. PEL does not guarantee any particular return or the performance of PEL.

## Distribution of presentation

This presentation must not be distributed in any jurisdiction to the extent that its distribution in that jurisdiction is restricted or prohibited by law or would constitute a breach by PEL of any law. The distribution of this presentation in jurisdictions outside New Zealand may be restricted by law, and persons into whose possession this presentation comes should observe any such restrictions. Any failure to comply with such restrictions may violate applicable securities laws. None of PEL, any person named in this presentation or any of their affiliates accept or shall have any liability to any person in relation to the distribution or possession of this presentation from or in any jurisdiction.

## Not for distribution or release in the United States

This presentation is not for distribution or release in the United States. This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States. The New Shares have not been, and will not be, registered under the US Securities Act of 1933, as amended, or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the US Securities Act of 1933, as amended, and applicable US state securities laws.

## Disclaimer

This presentation has been authorised for release to NZX and ASX by PEL's board of directors. None of PEL's advisers or any of their respective affiliates, related bodies corporate, directors, officers, partners, employees and agents, have authorised, permitted or caused the issue, submission, dispatch or provision of this presentation and, except to the extent referred to in this presentation, none of them makes or purports to make any statement in this presentation and there is no statement in this presentation which is based on any statement by any of them.

To the maximum extent permitted by law, PEL and its advisers, affiliates, related bodies corporate, nor their respective directors, officers, partners, employees and agents:

- exclude and disclaim all liability for any expenses, losses, damages or costs incurred by investors as a result of investors' participation in the Offer and/or the information in this presentation being inaccurate or incomplete in any way for any reason, whether by negligence or otherwise; and
- make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this presentation; and none of them shall have any liability (including for negligence) arising in connection with this presentation or the information contained in it.


By receiving this presentation, you agree to the above terms and conditions. All information in this presentation is provided as at 22 September 2021

# CONTENTS

1. EXECUTIVE SUMMARY
2. CAPITAL RAISING OVERVIEW
3. COMMERCIAL AND STRATEGIC PROGRESS

## APPENDICES

- A. THE GLOBAL OPPORTUNITY FOR CXBLADDER
- B. KEY RISKS & FOREIGN SELLING RESTRICTIONS



A globally focused cancer  
diagnostics company specialising  
in developing and  
commercialising molecular  
diagnostic tests that address  
large unmet needs in the  
detection and management  
of cancer

## EXECUTIVE SUMMARY

# PACIFIC EDGE AT A GLANCE

## A GLOBAL CANCER DIAGNOSTICS COMPANY

### Validated and class leading suite of Cxbladder products

- Four urine-based diagnostic tests (Cxbladder) for the detection and management of Urothelial Cancer (UC)
- First new molecular diagnostic tests to be commercially reimbursed in the U.S. for UC in 19 years
- Commercial sales in New Zealand, Australia, Singapore and the U.S.
- CMS reimbursement and product specific CPT codes for Cxbladder Detect and Cxbladder Monitor

### Portfolio of intellectual property and clinical evidence

- Products are underpinned by extensive clinical evidence published in top-tier international journals
- Potential to leverage existing intellectual property into new product development for the detection and management of other cancers that can be detected in urine

### Compelling growth opportunity

- Annual addressable market (AAM) for Cxbladder in the U.S. estimated to be more than US\$3.5b\*
- Laboratory infrastructure in place in New Zealand and the U.S. with a combined design capacity for 300k tests per annum
- Dedicated and growing US sales force in place to drive test growth



# FY21 WAS A YEAR OF ACHIEVEMENT

## SIGNIFICANT COMMERCIAL AND FINANCIAL MILESTONES DRIVE GROWTH

### Commercial Milestones

#### New Zealand

- More than 70% of New Zealand's population now have access to Cxbladder through contract coverage by their public healthcare providers

#### United States

- CMS reimbursement for Cxbladder Detect and Cxbladder Monitor
- Commercial agreement with Kaiser Permanente for Cxbladder tests
- Increased specialist sales force on ground in U.S.
- Federal Supply Schedule and contract price for Veterans Administration (achieved prior to FY21)

#### Global

- Publication of clinical evidence highlighting the clinical utility of Cxbladder
- Continuing evaluation and use of Cxbladder by large healthcare institutions



### Financial Milestones

- Strong (76%) growth in operating revenue across FY21
- Significant (52%) increase in cash receipts across FY21
- Reduction in monthly cash burn
- Clear (25%) improvement in net loss after tax across FY21
- Inclusion in the S&P NZX 50 index

# STRENGTHENED TEAM

## SENIOR MANAGEMENT & BOARD OF DIRECTORS

New appointments in the past 12 months add expertise and experience as Pacific Edge accelerates its global growth strategy

Global Executive Team	
Chief Executive Officer	David Darling*
Chief Financial Officer	Grant Gibson
<b>Chief Operational Officer</b>	<b>Demi Stefanova</b>
<b>Chief Information Systems &amp; Decision Support</b>	<b>Andy McIntosh</b>
<b>Chief Technical Officer</b>	<b>Justin Harvey</b>
VP Commercial & Franchise	Brent Pownall
VP Clinical Science & Product Performance	Tony Lough


PEDUSA Executive Team	
<b>Executive Chairman PEDUSA</b>	<b>David Levison</b>
CEO PEDUSA	Jackie Walker
VP Sales & Customer Service PEDUSA	Jack Atchason
Chief Medical Officer and Laboratory Director PEDUSA	Thomas Nifong
VP Marketing PEDUSA	Gerhard Schultz

Board of Directors	
Chairman (Australian based)	Chris Gallaher
Executive Director	David Darling
Independent Directors: • NZ based • NZ based • Australian based	Anatole Masfen Sarah Park Bryan Williams
<b>Independent Directors appointed in 2021 (NZ based)</b>	<b>Mark Green</b> <b>Anna Stove</b>

 Appointed in last 12 months

# FY21 DELIVERED STRONG IMPROVEMENT ACROSS KEY FINANCIAL METRICS, DESPITE THE IMPACT OF COVID-19\*

- ✓ 101% increase in total revenue
- ✓ 76% increase in operating revenue
- ✓ 25% improvement in net loss after tax
- ✓ 52% increase in cash receipts



\*Covid-19 impacted Pacific Edge's commercial programme in FY21 and continues to have an impact in FY22. Despite this, Pacific Edge has continued to grow



# GROWTH CONTINUES IN FY22


The first quarter of FY22\* was a record quarter for Cxbladder test volumes and cash receipts

## Q1 FY22 Total Laboratory Throughput:

- ✓ Up 79% on Q1 FY21
- ✓ Up 9% on Q4 FY21
- ✓ Up 35% on quarterly average in FY21

## Q1 FY22 Cash Receipts:

- ✓ Up 142% on Q1 FY21
- ✓ Up 21% on Q4 FY21
- ✓ Up 50% on quarterly average in FY21



# OUTLOOK

- Pacific Edge has a defined growth strategy and is well positioned to capitalise on recent commercial milestones
- The U.S. remains Pacific Edge's primary near term focus:
  - An increasing number of commercially reimbursed tests from CMS and Kaiser Permanente covered patients are currently expected to underpin strong revenue growth and growth in cash receipts in FY22 and beyond;
  - Positive results from the recent scale-up of U.S. commercial operations are now starting to be seen;
  - United Healthcare\* coverage provides validation supporting the potential adoption and coverage of Cxbladder with other private payers in the U.S.
- Strong growth continues in New Zealand with customers moving to multiple Cxbladder products in mainstream use
- Southeast Asia has the potential to become a market of scale over time with an accessible population base larger than the U.S.
- Australia is in the early stages of commercial take-up and there exists an opportunity to deliver sales and volume growth
- Potential to develop and grow new product opportunities by leveraging the company's intellectual property across other cancers that can be detected in urine

\* Currently Medicare Advantage policyholders





# CAPITAL RAISING OVERVIEW

# RAISING CAPITAL TO ACCELERATE GROWTH AND ASX DUAL LISTING

- Pacific Edge's priority is to ensure it has the resources and capacity to capitalise on its recent commercial milestones and to execute and accelerate its growth strategy in markets of scale
- Funds raised will be used as follows:
  - The majority of the funds will be used to accelerate penetration in the company's key U.S. market
  - To further grow in Southeast Asia
  - To further leverage the company's first mover advantage in the detection and management of urothelial cancer
  - To potentially develop and grow new product opportunities by leveraging the company's intellectual property across other cancers that can be detected in urine
  - To maintain a prudent cash buffer for balance sheet management and working capital purposes as the company transitions to profitability
- Pacific Edge was admitted to the official list of ASX as a foreign-exempt issuer on 22 September 2021 and currently expects that its shares will commence trading on the ASX on 27 September 2021
- Pacific Edge intends to maintain its primary listing on the NZX, and is committed to remaining a New Zealand company with its head office domiciled in New Zealand

# CAPITAL RAISING OVERVIEW

<b>Offer size and structure</b>	<ul style="list-style-type: none"> <li>An equity raising, comprising:             <ul style="list-style-type: none"> <li>A NZ\$60 million (A\$58.1 million)* Placement, equating to 5.6% of Pacific Edge’s current market capitalisation</li> <li>A NZ\$20 million (A\$19.4 million) Retail Offer (with the ability to accept over subscriptions at the Board's discretion)</li> </ul> </li> </ul>
<b>Placement Offer Price</b>	<ul style="list-style-type: none"> <li>The Placement Offer Price will be determined via a bookbuild process, with further details on bookbuild participation to be provided by the Joint Lead Managers</li> </ul>
<b>Retail Offer details</b>	<ul style="list-style-type: none"> <li>Pacific Edge is offering up to NZ\$20 million (A\$19.4 million) of newly issued ordinary shares (with the ability to accept over subscriptions at the Board's discretion) to Pacific Edge’s eligible existing shareholders resident in New Zealand (up to a maximum of NZ\$50,000 per shareholder) under a Retail Offer:             <ul style="list-style-type: none"> <li>The Retail Offer will be priced at the lower of the Placement Price or five day VWAP on NZX during the last five days of the Retail Offer period</li> </ul> </li> </ul>
<b>Ranking</b>	<ul style="list-style-type: none"> <li>The new shares to be issued under both the Placement and Retail Offer will on allotment rank equally in all respects with Pacific Edge’s existing ordinary shares</li> </ul>
<b>Arrangers</b>	<ul style="list-style-type: none"> <li>Bell Potter, Forsyth Barr and Jarden are acting as Joint Lead Managers</li> <li>Neither the Placement or the Retail Offer are underwritten</li> </ul>

\*Pacific Edge and the Joint Lead Managers reserve the right to vary the size of the placement based on the size, quality and price level of investor demand

\* Based on a NZD/AUD exchange rate of 0.9683 at 22 September 2021

# INTENDED USE OF PROCEEDS

## ACCELERATE MARKET PENETRATION IN THE U.S. AND SOUTHEAST ASIA

### Accelerate U.S. market penetration (40-50% of funds raised):

- Key growth initiatives include:
  - Initiate commercial launch of Cxbladder Resolve and the use of multiple Cxbladder tests used in combination, in FY22
  - Accelerate U.S. market penetration with new account managers, commercial support and increased marketing and advertising spend:
    - targeting increased Cxbladder adoption and sales through growing usage by existing customers, including large urology groups, large national customers, community practices and private payers
  - Generation and publication of new clinical evidence to support additional U.S. guideline inclusion and greater adoption of Cxbladder

### Initiate and develop new commercial business of scale in Southeast Asia (10-20% of funds raised):

- Key growth initiatives include:
  - Establish dedicated sales teams targeting Singapore, Indonesia, Philippines, Thailand and Malaysia, as large markets with healthcare models suited to the use of Cxbladder
  - Publication of clinical evidence from recently completed User Programs from five public hospitals in Singapore
  - Develop and grow existing and new commercial relationships with large private healthcare providers
  - Evaluate the opportunity to increase usage of Cxbladder with public healthcare providers

# INTENDED USE OF PROCEEDS (CONT)

## LEVERAGE FIRST MOVER ADVANTAGE IN UROTHELIAL CANCER AND IP PORTFOLIO

### Further leverage first mover advantage (20-30% of funds raised):

- Pacific Edge is uniquely positioned with strong first mover advantage in the detection of urothelial cancer and multiple Cxbladder products. It has taken years of investment to develop, validate and protect its IP and has achieved major U.S. reimbursement milestones, including CMS
- Capital raised will assist to sustain and leverage this competitive advantage to drive sales growth
- Key growth initiatives include:
  - Evaluating new product technologies and platforms to maximise performance for the existing Cxbladder product portfolio, cementing Cxbladder as the standard of care for the detection and management of urothelial cancer
  - Further increase Cxbladder's portfolio of clinical evidence through additional clinical studies, with clinical study outputs closely aligned to guideline inclusion
  - Potentially developing and growing new product opportunities by leveraging the company's intellectual property across other cancers that can be detected in urine

## BALANCE SHEET MANAGEMENT AND WORKING CAPITAL

### Balance sheet flexibility (20-30% of funds raised):

- Pacific Edge's cash balance as at 31 August 2021 was \$16.2 million, with the monthly cash burn for the last 12 months averaging \$1.36 million per month
- Pacific Edge considers it prudent to maintain a cash buffer, for balance sheet management and working capital purposes as the company transitions to profitability

# TIMETABLE

<b>Placement</b>	
Placement conducted under trading halt	23 September 2021
Announce completion of placement and trading halt lifted on NZX	No later than immediately prior to market open on 24 September 2021
Settlement, allotment and trading of placement shares on NZX commence	30 September 2021
<b>ASX dual listing</b>	
Pacific Edge admitted to official list of the ASX	22 September 2021
Pacific Edge shares commence trading on the ASX	27 September 2021
ASX settlement of placement	29 September 2021
ASX allotment of placement shares and trading of placement shares on the ASX	30 September 2021
<b>Retail Offer</b>	
Record date	5.00pm on 22 September 2021
Retail Offer opens and documentation sent to eligible shareholders	28 September 2021
Retail Offer closes	13 October 2021
Retail Offer settlement, shares allotted and commencement of trading	20 October 2021

Dates are subject to change at the discretion of Pacific Edge



## New Zealand

- Continued commercial adoption of Cxbladder, with the objective to complete coverage of the New Zealand population

## United States

- CMS reimbursement
- Kaiser Permanente
- United Healthcare\*
- Scale up of U.S. commercial operations
- Federal Supply Schedule contract

## Global

- Clinical evidence
- Continuing evaluation and use of Cxbladder by large healthcare institutions


\* Medicare Advantage

# COMMERCIAL AND STRATEGIC PROGRESS

# NEW ZEALAND IS LEADING THE GLOBAL ADOPTION OF CXBLADDER


- More than 70% of New Zealand's population now have access to Cxbladder through contract coverage by their public healthcare providers, who have adopted Cxbladder into commercial mainstream use and their standard of care
- New electronic guideline 'Health Pathways' with Cxbladder Triage and imaging for all haematuria patients - replacing previous gold standard cystoscopy and other tests and procedures

## Contract Coverage of New Zealand's Population Using Cxbladder, August 2021



# SIGNIFICANT U.S. TOTAL ADDRESSABLE MARKET

A MORE THAN US\$3.5 BILLION OPPORTUNITY FOR CXBLADDER PRODUCTS IN BOTH THE EVALUATION OF HAEMATURIA AND MONITORING FOR DISEASE RECURRENCE



# REIMBURSEMENT COVERAGE BY THE CMS PROVIDES A SIGNIFICANT VALIDATION AND COMMERCIAL MILESTONE

The successful LCD decision has allowed Pacific Edge to start recognising revenue (under NZ IFRS 15) for tests that are performed on CMS patients (Medicare and Medicare Advantage) in the US at the CMS price of US\$760 per test for Medicare

- CMS\* reimbursement coverage for Cxbladder Detect and Cxbladder Monitor from 1 July 2020 at US\$760 per test
- CMS related tests (Medicare and Medicare Advantage) accounted for 67% of U.S. commercial test volumes in FY21
- Cxbladder Detect and Cxbladder Monitor accounted for the majority of U.S. commercial test volumes in FY21
- Inclusion in the CMS's Local Coverage Determination (LCD) has resulted in a significant increase in recognised revenue and cash receipts – with CMS tests paid in approximately 30 days
- Many global healthcare providers regard CMS reimbursement as a significant validation – which is expected to pave the way for wider adoption

\* Centers for Medicare and Medicaid Services: US National insurance payer for all US citizens over 65 years of age



## KAISER PERMANENTE: LARGE COMMERCIAL CUSTOMER FOR CXBLADDER AND PROVIDES SIGNIFICANT VALIDATION

- Kaiser Permanente (Kaiser) has concluded a national agreement with Pacific Edge for Cxbladder products
- Kaiser started commercially using Cxbladder Monitor from December 2020, followed by Cxbladder Triage from August 2021
- Kaiser is utilising Cxbladder's Patient In-Home Sampling System for its patients, with the process managed by Pacific Edge
- Kaiser reported approximately 15% of consultations were telehealth prior to Covid-19. The proportion of telehealth consultations are reported by Kaiser to have increased to around 95% during Covid-19
- Kaiser is the largest non-profit healthcare provider in the U.S. with over 12 million members (approximately 3.8% of the U.S. population), 39 hospitals and approximately 23,000 physicians. Kaiser is reported to manage ~2% of U.S. urology patients
- Around 800,000 people in the U.S. are reportedly monitored for urothelial cancer, up to 4 times per year for 5 years

## CXBLADDER COVERED BY UNITED HEALTHCARE



## UNITED HEALTHCARE COVERAGE IS A SIGNIFICANT REIMBURSEMENT MILESTONE

- United Healthcare is the largest private healthcare provider in the U.S. with over 43 million members, including more than 6.5 million Medicare Advantage policyholders
- Cxbladder is being covered as a 'medically necessary bladder tumor marker test'
- Coverage became effective from 1 April 2021 at US\$760 per test
- United Healthcare partners with 6,500 hospitals and care facilities nationwide, and more than 1.2 million physicians and other providers


# SCALE-UP OF U.S. COMMERCIAL OPERATIONS IS DRIVING GROWTH

PACIFIC EDGE HAS STRENGTHENED ITS U.S. BASED EXECUTIVE AND SENIOR MANAGEMENT TEAM

EXPANDING US SALES  
TEAM:  
**25 ACCOUNT MANAGERS  
AS AT 30 JUNE 2021**



U.S. LABORATORY DESIGN  
CAPACITY:  
**260,000 TESTS P.A**



- Pacific Edge is growing its US based sales teams to accelerate the adoption of Cxbladder following the successful achievement of CMS, Kaiser Permanente and United Healthcare (Medicare Advantage) commercial milestones
- An additional 9 account managers added to existing and new sales territories in the past 8 months
- Continued focus by specialist account managers on converting large national healthcare providers into commercial customers
- Continue negotiations with specific targeted healthcare payers to enter into the network for reimbursement
- Expansion of customer services team to drive Patient In-Home Sampling System program for Kaiser and others

# PIVOTAL PAPER HIGHLIGHTS

## SIGNIFICANT OUTPERFORMANCE OF CXBLADDER PRODUCTS

- A pivotal, peer-reviewed paper co-authored by leading U.S. urologists and accepted for publication in the *Journal of Urology*\*
- Demonstrates the significant clinical and patient benefits from the use of a combination of Cxbladder products to correctly identify haematuria patients who have UC and segregates those patients with High-Impact Tumours (HIT) requiring priority investigation

\* The *Journal of Urology* is the official journal of the American Urological Association (AUA) and the most widely read and highly cited journal in the field of Urology. The paper was accepted for publication on 8 July 2021

- The paper titled 'Cxbladder for prioritising patients with high impact tumours' evaluates the use of Cxbladder Resolve (CxbR), alone and in combination with other Cxbladder tests, to identify and prioritise patients at high risk for UC
- CxbR was designed for use by a physician following a patient's initial evaluation using both Cxbladder Triage (CxbT) and Cxbladder Detect (CxbD). Those patients that test positive to CxbT and then also test positive to CxbD, will receive the CxbR test.
- CxbR was developed on 863 haematuria patients recruited in the U.S., NZ and Australia; and then tested, both separately and in combination with other Cxbladder tests, on a further 548 Kaiser Permanente patients, with outstanding results
- The paper concluded that CxbR has high sensitivity (92.4%) and specificity (93.8%) and correctly identified all high-impact tumours (HITs)
- With the sequential use of Cxbladder tests for each patient (CxbT followed by CxbD followed by CxbR):
  - 87.6% of patients were correctly ruled out from requiring further workup; and
  - 100% of high-impact tumours were accurately identified for prioritised investigation in both study cohorts
- Sequential use of Cxbladder provided 4.8x greater diagnostic efficiency than the latest American Urological Association (AUA) guidelines



# RECENT PUBLISHED EVIDENCE SHOWS SIGNIFICANT OUTPERFORMANCE OF CXBLADDER PRODUCTS

**American Urological Association's (AUA)  
Journal of Urology is publishing in September  
2021 a "real world lookback study"  
highlighting the clinical utility of Cxbladder  
Monitor being used in the Covid setting for  
managing patients outside the clinic**

The clinical paper was authored by Carrisa Chu, Kevin Li, Maxwell Meng and Sima Porten from the Department of Urology at the University of California San Francisco. The paper has been published in September 2021 of the Journal of Urology, the official journal of the American Urological Association (AUA)

## CXBLADDER PROVIDES SIGNIFICANT PATIENT OUTCOMES IN REAL-WORLD COVID-19 SETTING

- The evaluation and lookback study was performed by the University of California San Francisco (UCSF) on a cohort of 52 patients who were being monitored for urothelial cancer as part of their standard of care
- The lookback study concluded that the use by physicians of Cxbladder Monitor and Pacific Edge's Patient-In-Home Sampling System reduced the number of cystoscopies required and was feasible and safe for patients being monitored for urothelial cancer during the Covid-19 pandemic
- In addition, the study concluded that Cxbladder could be used to further stratify low risk patients for decreased surveillance during the pandemic and beyond
- Pacific Edge management summary of Cxbladder's performance in this publication:
  - 67% of all patients were ruled out from further work-up
  - All patients who were ruled out, that have subsequently been evaluated at the next scheduled surveillance (91%), had no tumors and no positive cytology (median 4 months)
  - 82% of patients with CxbM > 3.5 (not ruled out) received cystoscopy
  - 50% of whom had biopsies with 86% having high impact tumors

# LARGE NATIONAL HEALTHCARE PROVIDERS AND PAYERS

## TARGETED BY PACIFIC EDGE ACROSS THE U.S., SOUTHEAST ASIA AND AUSTRALASIA

U.S.	U.S.	SOUTHEAST ASIA
<ul style="list-style-type: none"> <li>✓ <b>Kaiser Permanente (completed)</b></li> <li>✓ <b>CMS reimbursement (completed)</b></li> <li>• Carolina Urologic Research Center</li> <li>• City of Hope</li> <li>• Cleveland Clinic</li> <li>• Cornell</li> <li>• Fox Chase CC</li> <li>• Johns Hopkins CC</li> <li>• MD Anderson</li> <li>• Moffitt CC</li> <li>• Ohio State University CC</li> <li>• Penn State Milton S. Hershey Medical Center</li> <li>• Rush University</li> <li>• Thomas Jefferson University</li> <li>• TriStar Medical Center</li> <li>• UCLA</li> </ul>	<ul style="list-style-type: none"> <li>✓ <b>United Healthcare (completed)*</b></li> <li>• University of California-San Diego</li> <li>• University of California-San Francisco</li> <li>• University of Chicago</li> <li>• University of Colorado</li> <li>• University of Michigan</li> <li>• University of Minnesota</li> <li>• University of Oklahoma</li> <li>• University of Pennsylvania</li> <li>• University of Southern California</li> <li>• UT Southwestern</li> <li>• VA Accounts</li> <li>• Wellstar</li> </ul> <p>* Medicare Advantage</p>	<ul style="list-style-type: none"> <li>• Singapore General Hospital</li> <li>• Tan Tock Seng</li> <li>• Khoo Tech Puat Hospital</li> <li>• KK Women's and Children's Hospital</li> <li>• National University Hospital</li> <li>• Raffles Medical Group</li> <li>• Gleneagles Private Hospital</li> </ul> <div style="background-color: #1a3d54; color: white; padding: 5px; text-align: center;"> <b>AUSTRALIA/NEW ZEALAND</b> </div> <ul style="list-style-type: none"> <li>• AUS: Multiple large public hospitals across Australia</li> <li>✓ <b>NZ: Majority of public healthcare providers under contract</b></li> </ul>




## APPENDIX A

# THE GLOBAL OPPORTUNITY FOR CXBLADDER

# UROTHELIAL CANCER IS A SIGNIFICANT GLOBAL HEALTHCARE CHALLENGE

- ~ 550,000 new cases in 2018<sup>1</sup>
- ~ 200,000 deaths annually<sup>1</sup>
- 10th most common cancer globally but 6th most common in men<sup>1</sup>
- High recurrence rates (around 70% recurrence following treatment)
- Requires regular monitoring
- High detection and management costs with invasive tests and procedures
- Patient compliance low ~40% leading to an increase in disease progression



1. Bray et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 3 cancers in 185 countries. *Ca Cancer J Clin.* 2018;68:394-424

# UROTHELIAL CANCER

## IS A SIGNIFICANT HEALTHCARE CHALLENGE IN THE U.S.

~7m patients present with haematuria annually and 3.4m are worked up to look for UC<sup>1</sup>

~4m cystoscopies were performed in 2018<sup>1</sup> (many of which are unnecessary and are replaceable with a non-invasive, accurate diagnostic test)

Approximately 83,730 estimated new cases of urothelial cancer are expected in the U.S. in 2021<sup>2</sup>

4th most common cancer in men in the U.S.<sup>3</sup>  
1 in 42 people will be diagnosed with UC in their lifetime<sup>4</sup>

More than 800,000 people living with UC will present annually up to 4 times a year for up to 5 years for evaluation for the recurrence of UC

Average lifetime costs of US\$220,000 per patient (recurrence rate of around 70% with expensive surveillance)<sup>1</sup>

Direct costs associated with UC predicted to reach US\$4.9b in 2020<sup>1</sup>



Based on direct costs alone, UC has the highest per patient treatment costs of any cancer over the patient lifetime<sup>1</sup>

1. Presentation from Dr Sia Daneshmand (Director of Urologic Oncology and Clinical Research, USC) July 2019
2. NIH National Cancer Institute, 2021
3. American Cancer Society, 2019
4. Bladder Cancer Advocacy Network, 2017


# EXISTING BLADDER CANCER TESTS AND PROCEDURES HAVE SIGNIFICANT SHORTCOMINGS...

...they are expensive, invasive and have poor relative performance ... providing significant opportunities for new diagnostic tests that are cheaper, non-invasive and accurate


	CYSTOSCOPY	CYTOLOGY	FISH
<b>USE</b>	Detection of bladder cancer	Identifying urothelial carcinoma	Conducted as a result of a typical cytology
<b>SOURCE MATERIAL</b>	Endoscopic procedure of the bladder	Whole cells that have sloughed off tumor and are caught in voided urine	Whole cells that have sloughed off tumor and are caught in voided urine
<b>RESULTS</b>	Performance does not meet the expectations of physicians; invasive and expensive	Subjective. High rate of atypical or suspicious findings	Quantitative (# of cells with aneuploidy.) Moderate rates of non-diagnostic results
<b>SENSITIVITY</b>	Sensitivity 71% and Specificity 65% <sup>2,3</sup>	Very low (32%-62%) <sup>1,2</sup>	Poor (39%) with high variability <sup>1</sup>



Normal



Cancer



# CXBLADDER REVOLUTIONIZES HOW UROLOGISTS DETECT AND MANAGE UROTHELIAL CANCER

- Four class leading, urine based diagnostic tests for UC addressing multiple unmet needs across the clinical pathway:
  - **Cxbladder Triage (CxbT)**: Front line test for use in the primary evaluation of haematuria to rule out patients who do not have cancer
  - **Cxbladder Detect (CxbD)**: For use by urologists for patients who have been referred for a full UC workup to detect cancers
  - **Cxbladder Resolve<sup>1</sup> (CxbR)**: Segregates High Impact Tumours (HIT) from Low Impact Tumours (LIT) enabling a prioritisation of patients with cancer
  - **Cxbladder Monitor (CxbM)**: Provides front line identification for urothelial cancer patients being monitored for recurrence of the disease
- Integrated into standards of care and guidelines for a number of healthcare providers in New Zealand and the NCCN guidelines in the U.S.



**Cxbladder provides better care for patients, better utility for urologists and savings for healthcare payers**

1. U.S. commercial launch of Cxbladder Resolve will be initiated in FY22

# CXBLADDER IS USED AT MULTIPLE DECISION POINTS ACROSS THE CLINICAL PATHWAY

	Cxbladder Triage	Cxbladder Detect	Cxbladder Resolve	Cxbladder Monitor
Patient Presentation	Primary Detection	Primary Detection		UC Surveillance
Risk stratification of patient	✓	✓	✓	
Chronic microhaematuria	✓	✓	✓	
Young, non-smoker, no occupational exposure, female	✓	✓	✓	
Gross haematuria	✓	✓	✓	
Atypical Cytology	✓	✓		
Equivocal cystoscopy	✓	✓		
Prioritisation of High Impact Tumours	✓	✓	✓	
Renal Insufficiency		✓		
Upper tract urothelial carcinoma		✓		
Surveillance for UC recurrence				✓





# CXBLADDER HAS CLASS LEADING PERFORMANCE METRICS: SENSITIVITY, SPECIFICITY AND NEGATIVE PREDICTIVE VALUE (NPV)

Primary Detection of UC - Haematuria

Surveillance of UC

Cxbladder Triage

Sensitivity 95%  
NPV 99%

Cxbladder Detect

Sensitivity 82%  
Specificity 85%  
NPV 97%

Cxbladder Resolve



Sensitivity 92%  
Specificity 94%  
NPV 99%

Cxbladder Monitor

Sensitivity 93%  
NPV 97%

Cxbladder's high sensitivity and high NPV provide the required confidence to rule out disease and significantly reduce the need for expensive, invasive tests

# CXBLADDER HAS A MULTI-MARKET AND MULTI-PRODUCT GROWTH OPPORTUNITY





## APPENDIX B

# KEY RISKS & FOREIGN SELLING RESTRICTIONS

# KEY RISKS

Like any investment, there are risks associated with an investment in Pacific Edge shares. Before investing in Pacific Edge, you should be aware that an investment in Pacific Edge has a number of risks, some of which are specific to Pacific Edge and some of which relate to listed securities generally, and many of which are beyond the control of Pacific Edge. Additionally, some risks may be unknown and other risks, currently believed to be immaterial, could turn out to be material. Whilst the section below aims to highlight some of the key risks, it is not exhaustive.

Investors should be aware that the spread of Covid-19 and the actions taken in response by governments in New Zealand and other countries, including border controls, stay at home measures and travel restrictions, and the resulting effects on the global economy have had, and may continue to have, a material adverse effect on Pacific Edge, its financial performance and position, liquidity, financial condition and results of operations. It is also likely that there will be further unforeseen negative impacts from the Covid-19 pandemic, of an as-yet unknown magnitude and duration. It is not currently clear when these negative impacts will begin to abate. Pacific Edge will continue to respond to the challenges facing it, but there is no certainty as to the severity or likelihood of such unforeseen impacts arising nor whether any mitigating action can be taken or will be effective.

Before deciding whether to invest in Pacific Edge shares, you must make your own assessment of the risks associated with the investment, including the inherent uncertainties due to the impact of Covid-19 noted above, and consider whether such an investment is suitable for you having regard to all other Pacific Edge continuous disclosure announcements and publicly available information, and consult your financial adviser and other professional advisers.

# KEY RISKS (CONT)

<b>Impact of Covid-19 on Pacific Edge</b>	<p>Pacific Edge’s operational and financial performance has been significantly impacted by Covid-19. This includes disruption to supply chains, which has the potential to impact Pacific Edge’s ability to procure equipment required to provide diagnostic tests; and border closures and travel restrictions, which limit Pacific Edge’s ability to both undertake in-person sales and marketing activity and recruit highly qualified employees.</p>
<b>General economic conditions</b>	<p>Pacific Edge’s operating and financial performance is influenced by a variety of general economic and business conditions in New Zealand, the United States, Southeast Asia and globally. A prolonged deterioration in general economic conditions, which may lead to a decrease or reprioritisation of healthcare spending, has the potential to have a material adverse effect on Pacific Edge’s business or financial condition (or both). This risk is heightened in the current uncertain economic environment.</p>
<b>Competition</b>	<p>The global cancer diagnostics industry is highly competitive, with research undertaken by a large number of commercial and not for profit institutions globally on new diagnostic tools. There are also a large number of well capitalised diagnostics competitors operating in the industry. There is a risk that Pacific Edge’s competitors may discover, develop or commercialise products more successfully than Pacific Edge, which could render Pacific Edge’s products obsolete or otherwise uncompetitive, resulting in adverse effects on Pacific Edge’s revenue, margins and profitability.</p>
<b>Product and technology risk</b>	<p>Pacific Edge relies on the performance and reliability of its Cxbladder suite of products, laboratory operations and IT and technical systems. While the performance of Cxbladder has been demonstrated in various scientific journal publications, any failure of Pacific Edge’s Cxbladder products and technology systems has the potential to impact Pacific Edge’s business and reputation. Financial and litigation consequences relating to underperformance and unreliability have the potential to be significant.</p>
<b>New product development</b>	<p>Pacific Edge continues to leverage its suite of patents and intellectual property to explore new products and applications. There is a risk that those development efforts may not be successful, or may take longer and be more expensive than anticipated, and as a result Pacific Edge’s investment will be delayed or lost. This risk could arise due to a number of factors, including delays in commencement or completion of scientific studies. Any failure or significant delay in the development of one or more of Pacific Edge’s new products and product extensions may have a material negative impact on Pacific Edge’s financial performance and growth.</p>

# KEY RISKS (CONT)

<b>Litigation</b>	<p>In the ordinary course of conducting its business, Pacific Edge is exposed to potential litigation and other proceedings, including through claims of intellectual property infringement or breach of agreements. If such proceedings are brought against Pacific Edge, Pacific Edge could incur considerable defence costs (even if successful), with the potential for damages and costs awards against Pacific Edge if it were unsuccessful, which could have a significant adverse financial impact on Pacific Edge.</p> <p>Circumstances may also arise in which Pacific Edge considers that it is reasonable or necessary to initiate litigation or other proceedings, including for example to protect its intellectual property rights.</p>
<b>Regulatory, industry body and guideline risks</b>	<p>Pacific Edge's Cxbladder products and laboratories are regulated and certified by various government and industry entities in territories and markets in which the tests are performed and/or sold. Reimbursement for these tests may be influenced by reimbursement rulings from private and/or government payers. Guidelines issued by various industry bodies also influence the treatment and management regimes for patients, with the potential to impact on the uptake and use of Cxbladder. If Pacific Edge is unable to retain or, in certain markets, gain inclusion in guidelines, or the current regulatory approvals and reimbursement obtained for existing products are removed or reduced, such matters could have an adverse impact on Pacific Edge's financial performance and its ability to achieve its business plans. If Pacific Edge is unable to obtain the approvals required for new products in new territories, or is unable to obtain future reimbursement for new products, this could also have an adverse impact on Pacific Edge's financial performance and its ability to achieve its business plans.</p>
<b>Market volatility of Pacific Edge's shares</b>	<p>Any investment in equity capital markets carries general risks. Pacific Edge's shares are currently listed on NZX, and will be listed on the ASX, and are subject to the usual market-related forces which impact on Pacific Edge's share price. There can be no assurance that trading in the shares following the offer will not result in the share price trading at levels below the price paid by investors in the offer. The equity markets have in recent times been subject to pronounced volatility due to the continuing impacts of Covid-19. There is no certainty that this recent volatility will not continue or worsen, which could have a materially adverse impact on the market price of Pacific Edge shares.</p> <p>Factors such as the risk factors disclosed in this presentation as well as other factors could cause the market price of Pacific Edge's shares to decline or to materially fluctuate. It also is possible that new market risks may develop as a result of the New Zealand market experiencing extreme stress, or due to existing risks (including the impacts of Covid-19) manifesting themselves in ways that are not currently foreseeable.</p> <p>A weakening in the New Zealand dollar as against other currencies will cause the value of the shares to decline in any portfolio which is denominated in a currency other than New Zealand dollars.</p>

# FOREIGN SELLING RESTRICTIONS

## International Offer Restrictions

This document does not constitute an offer of new ordinary shares (New Shares) of Pacific Edge in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Shares, may not be offered or sold in any country outside NZ except to the extent permitted below.

## Australia

This document and the offer of New Shares are only made available in Australia to persons to whom an offer of securities can be made without disclosure in accordance with applicable exemptions in sections 708(8) (sophisticated investors), 708(11) (professional investors), 761G (wholesale clients) of the Australian Corporations Act 2001 (Cth) (the "Corporations Act"). This document is not a prospectus, product disclosure statement or any other formal "disclosure document" for the purposes of Australian law and is not required to, and does not, contain all the information which would be required in a "disclosure document" under Australian law. This document has not been and will not be lodged or registered with the Australian Securities & Investments Commission. Prospective investors should not construe anything in this document as legal, business or tax advice nor as financial product advice for the purposes of Chapter 7 of the Corporations Act.

## Hong Kong

WARNING: This document has not been, and will not be, registered as a prospectus under the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong, nor has it been authorised by the Securities and Futures Commission in Hong Kong pursuant to the Securities and Futures Ordinance (Cap. 571) of the Laws of Hong Kong (the "SFO"). Accordingly, this document may not be distributed, and the New Shares may not be offered or sold, in Hong Kong other than to "professional investors" (as defined in the SFO and any rules made under that ordinance).

No advertisement, invitation or document relating to the New Shares has been or will be issued, or has been or will be in the possession of any person for the purpose of issue, in Hong Kong or elsewhere that is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to New Shares that are or are intended to be disposed of only to persons outside Hong Kong or only to professional investors. No person allotted New Shares may sell, or offer to sell, such securities in circumstances that amount to an offer to the public in Hong Kong within six months following the date of issue of such securities.

The contents of this document have not been reviewed by any Hong Kong regulatory authority. You are advised to exercise caution in relation to the offer. If you are in doubt about any contents of this document, you should obtain independent professional advice.

## Not for distribution in the United States

This presentation is not for distribution or release in the United States. This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States. The New Shares have not been, and will not be, registered under the US Securities Act of 1933, as amended, or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the US Securities Act of 1933, as amended, and applicable US state securities laws.